全文获取类型
收费全文 | 1261篇 |
免费 | 62篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 28篇 |
妇产科学 | 25篇 |
基础医学 | 100篇 |
口腔科学 | 57篇 |
临床医学 | 100篇 |
内科学 | 451篇 |
皮肤病学 | 6篇 |
神经病学 | 71篇 |
特种医学 | 78篇 |
外科学 | 220篇 |
综合类 | 5篇 |
预防医学 | 29篇 |
眼科学 | 24篇 |
药学 | 41篇 |
肿瘤学 | 92篇 |
出版年
2023年 | 14篇 |
2022年 | 17篇 |
2021年 | 48篇 |
2020年 | 29篇 |
2019年 | 29篇 |
2018年 | 36篇 |
2017年 | 20篇 |
2016年 | 41篇 |
2015年 | 24篇 |
2014年 | 56篇 |
2013年 | 69篇 |
2012年 | 112篇 |
2011年 | 108篇 |
2010年 | 66篇 |
2009年 | 50篇 |
2008年 | 97篇 |
2007年 | 102篇 |
2006年 | 111篇 |
2005年 | 74篇 |
2004年 | 61篇 |
2003年 | 42篇 |
2002年 | 30篇 |
2001年 | 12篇 |
2000年 | 14篇 |
1999年 | 8篇 |
1998年 | 7篇 |
1997年 | 8篇 |
1996年 | 5篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1976年 | 2篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1967年 | 1篇 |
1962年 | 1篇 |
1960年 | 1篇 |
1940年 | 2篇 |
排序方式: 共有1340条查询结果,搜索用时 31 毫秒
51.
Schmitt A Reinhardt P Hus I Tabarkiewicz J Roliñski J Barth T Giannopoulos K Dmoszyñska A Wiesneth M Schmitt M 《Transfusion》2007,47(9):1588-1594
BACKGROUND: Mononuclear cells (MNCs) of severely impaired acute myeloid leukemia (AML) patients may be collected by leukapheresis for large-scale generation of dendritic cells (AML-DCs) under good manufacturing practice (GMP) conditions for adoptive immunotherapy. STUDY DESIGN AND METHODS: In five end-stage AML patients, a leukapheresis procedure was performed with a cell separator (either COBE Spectra [Gambro BCT] or Amicus [Baxter]). For large-scale AML-DC generation, the MNCs of a single leukapheresis concentrate were isolated by density gradient and plated into a cell factory under GMP conditions. The AML-DCs were harvested on Day 8 of culture, and their viability, the mature morphology, and the phenotype were evaluated. The AML-DCs were injected subcutaneously into five AML patients up to four times at a biweekly interval. RESULTS: All AML patients entered the leukapheresis procedure with a highly pathologic blood count. In a mean separation time of 198 +/- 33 minutes, a mean of 1.3 +/- 0.2-fold the total blood volume was processed with a white blood cell (WBC) yield of 9 x 10(9) to 70 x 10(9) per collection dependent on the precollection WBC count. After density gradient a mean of 2.2 x 10(9) +/- 0.3 x 10(9) MNCs were plated into a cell factory. This resulted in a mean viable and mature DC yield of 0.01 x 10(9) of MNCs. CONCLUSION: The leukapheresis procedure is a feasible and safe procedure even in patients with hematologic malignancies and highly pathologic blood counts. Sufficient amounts of MNCs can be collected in leukopenic patients and the large-scale generation of AML-DCs in cell factories under GMP conditions yields in an adequate quantity of viable and mature AML-DCs. 相似文献
52.
Texakalidis Pavlos Karasavvidis Theofilos Giannopoulos Stefanos Tzoumas Andreas Charisis Nektarios Jabbour Pascal Machinis Theofilos Rangel-Castilla Leonardo Reavey-Cantwell John 《Neurosurgical review》2020,43(3):931-940
Neurosurgical Review - Extracranial internal carotid artery dissection (ICAD) is a potential source of morbidity and mortality in trauma patients and requires high degree of suspicion for diagnosis... 相似文献
53.
Katja Findeisen Lucrezia Morticelli Tobias Goecke Louisa Kolbeck Robert Ramm Hans-Klaus Höffler Gudrun Brandes Sotirios Korossis Axel Haverich Andres Hilfiker 《Xenotransplantation》2020,27(5):e12617
The use of decellularized xenogeneic heart valves might offer a solution to overcome the issue of human valve shortage. The aim of this study was to revise decellularization protocols in combination with enzymatic deglycosylation, in order to reduce the immunogenicity of porcine pulmonary heart valves, in means of cells, carbohydrates, and, primarily, Galα1-3Gal (α-Gal) epitope removal. In particular, the valves were decellularized with sodium dodecylsulfate/sodium deoxycholate (SDS/SD), Triton X-100 + SDS (Tx + SDS), or Trypsin + Triton X-100 (Tryp + Tx) followed by enzymatic digestion with PNGaseF, Endoglycosidase H, or O-glycosidase combined with Neuraminidase. Results showed that decellularization alone reduced carbohydrate structures only to a limited extent, and it did not result in an α-Gal free scaffold. Nevertheless, decellularization with Tryp + Tx represented the most effective decellularization protocol in means of carbohydrates reduction. Overall, carbohydrates and α-Gal removal could strongly be improved by applying PNGaseF, in particular in combination with Tryp + Tx treatment, contrary to Endoglycosidase H and O-glycosidase treatments. Furthermore, decellularization with PNGaseF did not affect biomechanical stability, in comparison with decellularization alone, as shown by burst pressure and uniaxial tensile tests. In conclusion, valves decellularized with Tryp + Tx and PNGaseF resulted in prostheses with potentially reduced immunogenicity and maintained mechanical stability. 相似文献
54.
Farmakis Dimitrios Chrysohoou Christina Giamouzis Gregory Giannakoulas George Hamilos Michalis Naka Katerina Tzeis Stylianos Xydonas Sotirios Karavidas Apostolos Parissis John 《Heart failure reviews》2021,26(6):1345-1358
Heart Failure Reviews - Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the... 相似文献
55.
56.
Wei-Jia Li Paraschos Archontakis-Barakakis Leonidas Palaiodimos Dimitrios Kalaitzoglou Lazaros Tzelves Apostolos Manolopoulos Yu-Chiang Wang Stefanos Giannopoulos Robert Faillace Damianos G Kokkinidis 《World journal of cardiology》2021,13(4):82-94
BACKGROUNDMost of the randomized clinical trials that led to the wide use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation (AF) originated from western countries. AIMTo systematically review and quantitatively synthesize the real-world data regarding the efficacy and safety of dabigatran, rivaroxaban, and apixaban compared to warfarin for stroke prevention in Asian patients with non-valvular AF.METHODSMedline, Cochrane, and ClinicalTrial.gov databases were reviewed. A random-effect model meta-analysis was used and I-square was utilized to assess the heterogeneity. The primary outcome was ischemic stroke. The secondary outcomes were all-cause mortality, major bleeding, intracranial hemorrhage, and gastrointestinal bleeding.RESULTSTwelve studies from East Asia or Southeast Asia and 441450 patients were included. Dabigatran, rivaroxaban, and apixaban were associated with a significant reduction in the incidence of ischemic stroke [hazard ratio (HR) = 0.78, 95% confidence interval (CI): 0.65-0.94; HR = 0.79, 95%CI: 0.74-0.85, HR = 0.70, 95%CI: 0.62-0.78; respectively], all-cause mortality (HR = 0.68, 95%CI: 0.56-0.83; HR = 0.66, 95%CI: 0.52-0.84; HR = 0.66, 95%CI: 0.49-0.90; respectively), and major bleeding (HR = 0.61, 95%CI: 0.54-0.69; HR = 0.70, 95%CI: 0.54-0.90; HR = 0.58, 95%CI: 0.43-0.78; respectively) compared to warfarin.CONCLUSIONDabigatran, rivaroxaban, and apixaban appear to be superior to warfarin in both efficacy and safety in Asians with non-valvular AF. 相似文献
57.
Georgios Giannopoulos Georgios Oudatzis Georgios Paterakis Andreas Synetos Eleni Tampaki Georgios Bouras George Hahalis Dimitrios Alexopoulos Dimitrios Tousoulis Michael W. Cleman Christodoulos Stefanadis Spyridon Deftereos 《International journal of cardiology》2014
Background
Red blood cell and platelet microparticles (RBCm and PLTm, respectively) have drawn research attention as to their potential prothrombotic and vasoconstrictive effects in experimental settings. However, the relevance of circulating microparticles in clinical settings is largely undetermined.Methods
Circulating microparticles were quantified with a flow cytometric method in blood samples from consecutive STEMI patients after primary PCI. A matched cohort of healthy volunteers was used to derive reference values for comparison. STEMI patients were followed for 6 months for a composite clinical endpoint.Results
Fifty-one STEMI patients (age 59.8 ± 8.8 years) and 50 controls (age 56.2 ± 9.2 years; p = 0.155) were enrolled. RBCm concentration was 18,198 ± 6062/μl in the reference cohort versus 33,740 ± 21,169/μl in STEMI patients (p < 0.001). RBCm count was not correlated to total RBCs (standardized beta 0.018; p = 0.861). PLTm did not differ between groups (17,529 ± 16,292/μl in STEMI patients versus 14,372 ± 6211/μl in controls; p = 0.203). RBCm c-statistic was 0.832 (95% confidence interval 0.720 to 0.944), while PLTm prognostic value was not statistically significant (c-statistic 0.614, 95% confidence interval 0.444 to 0.784). In the multivariate analysis, RBCm concentration was independently associated with the occurrence of the clinical endpoint, after adjustment for age, ejection fraction, serum creatinine and presence of diabetes (adjusted p = 0.034).Conclusions
The present study demonstrates for the first time that erythrocyte microparticles are elevated in patients with STEMI treated with primary PCI, with levels approximately double those measured in a reference population of healthy volunteers, and their concentrations appear to be positively associated with adverse clinical events. 相似文献58.
59.
John V. Asimakopoulos Maria K. Angelopoulou Maria-Panagiota Arapaki Alexandros Kanellopoulos Maria Dimou Xanthoula Giakoumis Eliana Konstantinou Marina Belia Chrysovalantou Chatzidimitriou Sotirios Sachanas Theodoros Iliakis Marie-Christine Kyrtsonis Marina P. Siakantaris Nora-Athina Viniou Eleni Variamis Flora N. Kontopidou Gerassimos A. Pangalis Panayiotis Panayiotidis Kostas Konstantopoulos Theodoros P. Vassilakopoulos 《British journal of haematology》2020,190(6):e335-e339